Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Syndax Terminates Entinostat License Agreement with EOC HK, Ending Jingzhuda Commercial Rights in China

Fineline Cube Aug 6, 2026
Company Deals

AstraZeneca and CSPC Pharmaceutical Establish Joint Venture for Next-Generation Biologics Manufacturing Base in Shijiazhuang

Fineline Cube Aug 6, 2026
Company Deals

Curium Pharma to Acquire Lantheus Holdings in $8 Billion Deal, Expanding Radiopharmaceutical Market Dominance

Fineline Cube Aug 5, 2026
Company Deals

Alphamab Oncology Secures $2.2B Deal with Pathos AI for JSKN016 Global Licensing

Fineline Cube Aug 5, 2026
Company Deals

Hunan Zonsen PepLib Biotech Secures Over RMB 300 Million in Series C Financing

Fineline Cube Aug 5, 2026
Policy / Regulatory

China’s CDE Releases 109th Reference Listed Drug Catalog, Adding 10 New Generic Drug Specifications

Fineline Cube Aug 6, 2026
Company Drug

Takeda Receives FDA Approval for ORZEYFUL (oveporexton), First Oral OX2R Agonist for Narcolepsy Type 1 in Adults

Fineline Cube Aug 6, 2026
Company Drug

Shandong Boan Biotech Submits BLA to Brazil’s ANVISA for Aflibercept Biosimilar BA9101, Expanding Global Ophthalmic Footprint

Fineline Cube Aug 6, 2026
Company Deals

Aidea Pharmaceutical to Boost Stake in Nanda Pharmaceutical to 51.1256%

Fineline Cube Jun 26, 2024

Jiangsu Aidea Pharmaceutical Co., Ltd (SHA: 688488), a pharmaceutical company based in China, is poised...

Company Drug

Sino Biopharmaceutical Gains NMPA Approval for Liraglutide Biosimilar for Type 2 Diabetes

Fineline Cube Jun 26, 2024

Sino Biopharmaceutical Ltd (HKG: 1177), a major player in China’s pharmaceutical industry, has announced that...

Company Drug

CSPC Pharmaceutical’s BCMA-Targeted CAR-T Therapy SYS6020 Receives NMPA Clinical Trial Approval

Fineline Cube Jun 26, 2024

CSPC Pharmaceutical Group Ltd (HKG: 1093), a leading pharmaceutical company based in China, has announced...

Company Drug

Novo Nordisk’s Semaglutide for Long-Term Weight Management Receives NMPA Approval

Fineline Cube Jun 26, 2024

Novo Nordisk (NYSE: NVO, CPH: NOVO-B), a leading healthcare company from Denmark, has announced that...

Company Drug

Jiangsu Simcere Pharmaceutical Wins NMPA Nod for Biosimilar Version of Erbitux

Fineline Cube Jun 26, 2024

Jiangsu Simcere Pharmaceutical Co., Ltd (HKG: 2096), a Chinese pharmaceutical company, has announced that it...

Company Deals

Walvax Biotechnology Halts COVID-19 mRNA Vaccine Trials Co-Developed with Abogen Biosciences

Fineline Cube Jun 26, 2024

Walvax Biotechnology Co., Ltd (SHE: 300142), a biopharmaceutical company based in China, has announced the...

Company Policy / Regulatory

U.S. Lawmakers Question FDA on Discrepancies in Foreign Inspections of China and India

Fineline Cube Jun 25, 2024

U.S. lawmakers have intensified their scrutiny of the FDA’s foreign inspection program, particularly for companies...

Company

Novo Nordisk to Pump USD 4.1 Billion into U.S. Manufacturing Expansion

Fineline Cube Jun 25, 2024

Novo Nordisk (NYSE: NVO), a Danish biopharmaceutical company, has announced plans to invest USD 4.1...

Company Drug

Merck KGaA’s Xevinapant Misses Primary Endpoint in Phase III Head and Neck Cancer Trial

Fineline Cube Jun 25, 2024

Merck KGaA (NYSE: MRK), a leading German pharmaceutical company, has encountered a setback in the...

Company Deals

Suzhou Porton Biologics Becomes First Chinese CDMO to Adopt MaxCyte’s ExPERT GTx Platform

Fineline Cube Jun 25, 2024

Suzhou Porton Biologics Ltd, a biopharmaceutical company based in China, has announced the introduction of...

Company Drug

J&J’s Tecvayli Earns NMPA Approval for Relapsed or Refractory Multiple Myeloma

Fineline Cube Jun 25, 2024

Johnson & Johnson (J&J; NYSE: JNJ), a leading U.S. healthcare company, has announced that it...

Company Drug

Alebund Pharmaceuticals’ AP306 Earns Breakthrough Designation for Chronic Kidney Disease

Fineline Cube Jun 25, 2024

Alebund Pharmaceuticals, based in Shanghai, has announced that its drug candidate AP306 (EOS789), a pan-inhibitor...

Company Drug

Staidson Pharmaceutical Gets FDA Clearance for TNFR2-Targeted mAb SBT-1901

Fineline Cube Jun 25, 2024

Staidson (Beijing) Pharmaceutical Co., Ltd (SHE: 300204), a biopharmaceutical company based in China, has announced...

Company Deals

Jiangsu Jibeier Pharm Completes Private Placement to Fund R&D Center on STAR Market

Fineline Cube Jun 25, 2024

Jiangsu Jibeier Pharm Co., Ltd (SHA: 688566), a Chinese pharmaceutical company, has announced the successful...

Company Drug

Hybio Pharmaceutical’s Biosimilar Liraglutide Gets Temporary FDA Nod Pending Patent Expiry

Fineline Cube Jun 25, 2024

Hybio Pharmaceutical Co., Ltd (SHE: 300199), a Chinese pharmaceutical company, has announced that it has...

Company Drug

Asieris Pharmaceuticals Gets NMPA Green Light for APL-1202 Clinical Trial in FLA Infections

Fineline Cube Jun 25, 2024

Asieris Pharmaceuticals (SHA: 688176), a Chinese specialist in urogenital cancer, has announced that it has...

Company Deals

Tonghua Dongbao Pharmaceuticals Partners with Sinopharm for Supply Chain and Market Expansion

Fineline Cube Jun 25, 2024

Tonghua Dongbao Pharmaceuticals (SHA: 600867), a Chinese pharmaceutical company, has entered into a strategic partnership...

Company Deals

Fosun Pharma to Take Henlius Private in Deal Valued at HKD 5.407 Billion

Fineline Cube Jun 25, 2024

Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) has announced plans to take...

Company Drug

Shanghai Haihe Pharmaceutical’s Glumetinib Earns Marketing Approval in Japan for NSCLC Treatment

Fineline Cube Jun 25, 2024

Shanghai Haihe Pharmaceutical Co., Ltd, a Chinese pharmaceutical company, has announced that it has received...

Company Deals

Sun Yat-sen University and KingMed Diagnostics Collaborate on Talent Development and Research

Fineline Cube Jun 25, 2024

On June 20, 2024, the School of Public Health (Shenzhen) of Sun Yat-sen University and...

Posts pagination

1 … 379 380 381 … 704

Recent updates

  • Gilead Sciences Reports Q2 2026 Revenue of $7.8B, Driven by HIV Franchise and Trodelvy Growth Despite Cell Therapy Decline
  • Astellas Reports Record Q1 FY2026 Revenue of ¥640.9B, Driven by Strategic Brands Growth and Raises Full-Year Outlook
  • Takeda Receives FDA Approval for ORZEYFUL (oveporexton), First Oral OX2R Agonist for Narcolepsy Type 1 in Adults
  • Syndax Terminates Entinostat License Agreement with EOC HK, Ending Jingzhuda Commercial Rights in China
  • Luye Pharma’s Novel VMAT2 Inhibitor LY03015 Completes US Bridging Trial with Enhanced Safety Profile in Caucasian Subjects
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company

Gilead Sciences Reports Q2 2026 Revenue of $7.8B, Driven by HIV Franchise and Trodelvy Growth Despite Cell Therapy Decline

Company

Astellas Reports Record Q1 FY2026 Revenue of ¥640.9B, Driven by Strategic Brands Growth and Raises Full-Year Outlook

Company Drug

Takeda Receives FDA Approval for ORZEYFUL (oveporexton), First Oral OX2R Agonist for Narcolepsy Type 1 in Adults

Company Deals

Syndax Terminates Entinostat License Agreement with EOC HK, Ending Jingzhuda Commercial Rights in China

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.